Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics (Nasdaq:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
Related news for (GLUE)
- Dealmaking Drives the Tape: These Stocks Are Heating Up into the Close
- Capital Meets Conviction: VENU, HSDT, GLUE, and IHT Show Investors the Money
- MoBot alert highlights: NASDAQ: SLRX, NASDAQ: GLUE, NASDAQ: DEVS, NASDAQ: CHEK, NYSE: ATCH (09/15/25 07:00 AM)
- Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
- 24/7 Market News Snapshot 15 September, 2025 – Monte Rosa Therapeutics, Inc. Common Stock (NASDAQ:GLUE)